Lotensin HCT (Benazepril Hydrochloride / Hydrochlorothiazide) - Indications and Dosage

INDICATIONS AND USAGE

Lotensin HCT is indicated for the treatment of hypertension.

This fixed combination drug is not indicated for the initial therapy of hypertension (see DOSAGE AND ADMINISTRATION).

DOSAGE AND ADMINISTRATION

Dose once daily. The dosage may then be increased after 2 to 3 weeks as needed to help achieve blood pressure goals. The maximum recommended dose is 20mg/25mg.

Switch Therapy:  A patient whose blood pressure is not adequately controlled with benazapril alone or with hydrochlorothiazide alone may be switched to combination therapy with Lotensin HCT. The usual recommended starting dose is 10/12.5 mg once daily to control blood pressure.

Replacement Therapy:  The combination may be substituted for the titrated individual components.

HOW SUPPLIED

Lotensin HCT is available in tablets of four different strengths:

Benazepril	Hydrochlorothiazide	Tablet Color
5 mg	6.25 mg	white
10 mg	12.5 mg	light pink
20 mg	12.5 mg	grayish-violet
20 mg	25 mg	red

Tablets of each strength are supplied in bottles that contain a desiccant and 100 tablets.

      The National Drug Codes for the various packages are

Dose	Bottle of 100	Tablet Imprint
5/6.25	NDC 0078-0451-05	57
10/12.5	NDC 0078-0452-05	72
20/12.5	NDC 0078-0453-05	74
20/25	NDC 0078-0454-05	75

Tablets are oblong and scored, with “Lotensin HCT” on one side and appropriate number imprinted on the other side.

Storage: Do not store above 30ºC (86ºF). Protect from moisture and light. Dispense in tight, light -resistant container (USP).

Manufactured by:
Novartis Pharmaceuticals Corporation
Suffern, New York 10901

Distributed by:
Novartis Pharmaceuticals Corporation
East Hanover, New Jersey 07936

© Novartis

T2013-28
April 2013